产品说明书
Cefoperazone
 |
同义名 : | - |
| CAS号 : | 62893-19-0 | |
| 货号 : | A194605 | |
| 分子式 : | C25H27N9O8S2 | |
| 纯度 : | 98% | |
| 分子量 : | 645.667 | |
| MDL号 : | MFCD00865067 | |
| 存储条件： |
粉末 Sealed in dry,2-8°C 液体 -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : |
DMSO: 105 mg/mL(162.62 mM)，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO |
|
| 动物实验配方： |
IP 2% DMSO+2% Tween80+30% PEG300+water 8 mg/mL clear PO 0.5% CMC-Na 54 mg/mL suspension |
| 生物活性 | |||
|---|---|---|---|
| 描述 | Cefoperazone is a third‐generation cephalosporin and is one of a small number of cephalosporins that are effective in treating Pseudomonas bacterial infections (MIC50 25 μg/mL). The hydrolysis product of cefoperazone was noncovalently bound in the active site of PBP3. This may be important in the design of new noncovalent PBP3 inhibitors[3]. After intramuscular injection of 2 g of cefoperazone, the mean peak serum level was 111 microgram/ml at 1.5 hours. At 12 hours after dosing, mean serum levels were still 2 to 4 microgram/ml. Cefoperazone was 90% bound to serum proteins[4]. Both the inhibitory potency of the cephalosporins for Mrp2-mediated (multidrug resistance-associated protein) transport and the uptake of cephalosporins by Mrp2-expressing vesicles were molecular weight-dependent[5]. | ||
| 临床研究 | |||||
|---|---|---|---|---|---|
| NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
| NCT02099240 | Osteomyelitis | Early Phase 1 | Recruiting | September 2019 | United States, Kentucky ... 展开 >> University of Louisville Recruiting Louisville, Kentucky, United States, 40202 Contact: Julio A Ramirez, MD 502-852-1148 jarami01@louisville.edu Contact: David Seligson, MD 502-852-0923 d0seli01@louisville.edu Sub-Investigator: Forest Arnold, DO Sub-Investigator: Timothy Wiemkwn, PhD Sub-Investigator: Robert Kelley, PhD Sub-Investigator: James Summersgill, PhD Sub-Investigator: Ruth Carrico, PhD Sub-Investigator: Julie Harting, PharmD Sub-Investigator: Paula Peyrani, MD Principal Investigator: David Seligson, MD Sub-Investigator: Craig Roberts, MD Principal Investigator: Julio Ramirez, MD 收起 << |
| NCT03003273 | Neutropenia, Febrile ... 展开 >> Pediatric Cancer 收起 << | Phase 3 | Recruiting | December 2018 | India ... 展开 >> Department of Medical Oncology, AIIMS Recruiting New Delhi, India, 110029 Contact: Sameer Bakhshi, MD 011-29575237 sambakh@hotmail.com 收起 << |
| NCT01601093 | Respiratory Tract Infections ... 展开 >> Urinary Tract Infections 收起 << | Phase 2 | Unknown | November 2013 | China, Jiangsu ... 展开 >> the First Affiliated Hospital With Medical University Recruiting Nanjing, Jiangsu, China Contact: hong wh wang, doctor 025-83714511 ext 6360 Sub-Investigator: mao hm huang, doctor 收起 << |
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
1.55mL 0.31mL 0.15mL |
7.74mL 1.55mL 0.77mL |
15.49mL 3.10mL 1.55mL |
